{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:38:40Z","timestamp":1789591120323,"version":"build-2803163510"},"reference-count":30,"publisher":"Japan Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1507\/endocrj.ej24-0032","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T22:12:12Z","timestamp":1719612732000},"page":"789-797","source":"Crossref","is-referenced-by-count":1,"title":["Vascular endothelial growth factor and endocan expression in adrenal cortical tumors and their relationship with histopathological prognostic parameters"],"prefix":"10.1507","volume":"71","author":[{"given":"Melia","family":"Karak\u00f6se","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Meram School of Medicine, Necmettin Erbakan University, Konya 42000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Can","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Mu\u015f State Hospital, Mu\u015f 49100, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammet","family":"Kocaba\u015f","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Meram School of Medicine, Necmettin Erbakan University, Konya 42000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hac\u0131","family":"Hasan Esen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Meram School of Medicine, Necmettin Erbakan University, Konya 42000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Kulaks\u0131zo\u011flu","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Meram School of Medicine, Necmettin Erbakan University, Konya 42000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feridun","family":"Karakurt","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Meram School of Medicine, Necmettin Erbakan University, Konya 42000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Aubert S, Wacrenier A, Leroy X, Devos P, Carnaille B, et al. (2002) Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol 26: 1612\u20131619.","DOI":"10.1097\/00000478-200212000-00009"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B (1995) Incidentally discovered adrenal masses. Endocr Rev 16: 460\u2013483.","DOI":"10.1210\/edrv-16-4-460"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, et al. (2014) Adrenocortical carcinoma. Endocr Rev 35: 282\u2013326.","DOI":"10.1210\/er.2013-1029"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Else T (2012) Association of adrenocortical carcinoma with familial cancer susceptibility syndromes. Mol Cell Endocrinol 351: 66\u201370.","DOI":"10.1016\/j.mce.2011.12.008"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Zhan P, Wang J, Lv XJ, Wang Q, Qiu LX, et al. (2009) Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol 4: 1094\u20131103.","DOI":"10.1097\/JTO.0b013e3181a97e31"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Hemmerlein B, Kugler A, Ozisik R, Ringert RH, Radzun HJ, et al. (2001) Vascular endothelial growth factor expression, angiogenesis, and necrosis in renal cell carcinomas. Virchows Arch 439: 645\u2013652.","DOI":"10.1007\/s004280100464"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Sarrazin S, Maurage CA, Delmas D, Lassalle P, Delehedde M (2010) Endocan as a biomarker of endothelial dysfunction in cancer. J Cancer Sci Ther 2: 47\u201352.","DOI":"10.4172\/1948-5956.1000022"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Huang X, Chen C, Wang X, Zhang JY, Ren BH, et al. (2016) Prognostic value of endocan expression in cancers: evidence from meta-analysis. Onco Targets Ther 9: 6297\u20136304.","DOI":"10.2147\/OTT.S110295"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Delehedde M, Devenyns L, Maurage CA, Viv\u00e8s RR (2013) Endocan in cancers: a lesson from a circulating dermatan sulfate proteoglycan. Int J Cell Biol 2013: 705027.","DOI":"10.1155\/2013\/705027"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Almumen M (2015) Immunohistochemical expression of VEGF in relation to other pathological parameters of breast carcinoma. J Cancer Ther 6: 811\u2013820.","DOI":"10.4236\/jct.2015.69089"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, et al. (2018) European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the european network for the study of adrenal tumors. Eur J Endocrinol 179: G1\u2013G46.","DOI":"10.1530\/EJE-18-0608"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12 Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249\u2013257.","DOI":"10.1038\/35025220"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Favier J, Plouin PF, Corvol P, Gasc JM (2002) Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am J Pathol 161: 1235\u20131246.","DOI":"10.1016\/S0002-9440(10)64400-8"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Murakami T, Oukouchi H, Uno Y, Ohtsuka A, Taguchi T (1989) Blood vascular beds of rat adrenal and accessory adrenal glands, with special reference to the corticomedullary portal system: a further scanning electron microscopic study of corrosion casts and tissue specimens. Arch Histol Cytol 52: 461\u2013476.","DOI":"10.1679\/aohc.52.461"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 de Fraipont F, El Atifi M, Gicquel C, Bertagna X, Chambaz EM, et al. (2000) Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations. J Clin Endocrinol Metab 85: 4734\u20134741.","DOI":"10.1210\/jc.85.12.4734"},{"key":"16","unstructured":"16 Kolomecki K, Stepien H, Bartos M, Kuzdak K (2001) Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours. Endocr Regul 35: 9\u201316."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Bernini GP, Moretti A, Bonadio AG, Menicagli M, Viacava P, et al. (2002) Angiogenesis in human normal and pathologic adrenal cortex. J Clin Endocrinol Metab 87: 4961\u20134965.","DOI":"10.1210\/jc.2001-011799"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18 Xu YZ, Zhu Y, Shen ZJ, Sheng JY, He HC, et al. (2011) Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy. Endocrine 40: 445\u2013451.","DOI":"10.1007\/s12020-011-9502-1"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Matano F, Yoshida D, Ishii Y, Tahara S, Teramoto A, et al. (2014) Endocan, a new invasion and angiogenesis marker of pituitary adenomas. J Neurooncol 117: 485\u2013491.","DOI":"10.1007\/s11060-014-1377-6"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Grigoriu BD, Depontieu F, Scherpereel A, Gourcerol D, Devos P, et al. (2006) Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res 12: 4575\u20134582.","DOI":"10.1158\/1078-0432.CCR-06-0185"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Leroy X, Aubert S, Zini L, Franquet H, Kervoaze G, et al. (2010) Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma. Histopathology 56: 180\u2013187.","DOI":"10.1111\/j.1365-2559.2009.03458.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Kroiss M, Quinkler M, Johanssen S, van Erp NP, Lankheet N, et al. (2012) Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab 97: 3495\u20133503.","DOI":"10.1210\/jc.2012-1419"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Berruti A, Sperone P, Ferrero A, Germano A, Ardito A, et al. (2012) Phase II study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol 166: 451\u2013458.","DOI":"10.1530\/EJE-11-0918"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 O\u2019Sullivan C, Edgerly M, Velarde M, Wilkerson J, Venkatesan AM, et al. (2014) The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. J Clin Endocrinol Metab 99: 1291\u20131297.","DOI":"10.1210\/jc.2013-2298"},{"key":"25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2407-8-14","volume":"18","author":"F Depontieu","year":"2008","unstructured":"25 Depontieu F, Grigoriu BD, Scherpereel A, Adam E, Delehedde M, et al. (2008) Loss of endocan tumorigenic properties after alternative splicing of exon 2. BMC Cancer 18: 14.","journal-title":"BMC Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2407","issn-type":"print"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Kang YH, Ji NY, Lee CI, Lee HG, Kim JW, et al. (2011) ESM-1 silencing decreased cell survival, migration, and invasion and modulated cell cycle progression in hepatocellular carcinoma. Amino Acids 40: 1003\u20131013.","DOI":"10.1007\/s00726-010-0729-6"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Zhao W, Sun M, Li S, Wang Y, Liu J (2014) Biological and clinical implications of endocan in gastric cancer. Tumor Biol 35: 10043\u201310049.","DOI":"10.1007\/s13277-014-2287-0"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Bender O, Gunduz M, Cigdem S, Hatipoglu OF, Acar M, et al. (2018) Functional analysis of ESM1 by siRNA knockdown in primary and metastatic head and neck cancer cells. J Oral Pathol Med 47: 40\u201347.","DOI":"10.1111\/jop.12648"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Chen C, Shin JH, Eggold JT, Chung MK, Zhang LH, et al. (2016) ESM1 mediates NGFR-induced invasion and metastasis in murine oral squamous cell carcinoma. Oncotarget 7: 70738\u201370749.","DOI":"10.18632\/oncotarget.12210"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Cai H, Yang X, Gao Y, Xu Z, Yu B, et al. (2019) Exosomal microRNA-9-3p secreted from BMSCs downregulates ESM1 to suppress the development of bladder cancer. Mol Ther Nucleic Acids 18: 787\u2013800.","DOI":"10.1016\/j.omtn.2019.09.023"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/71\/8\/71_EJ24-0032\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T04:09:02Z","timestamp":1723262942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/71\/8\/71_EJ24-0032\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej24-0032","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"EJ24-0032"}}